140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

Authors :: Amita Patnaik
Tara C. Gangadhar
Adil Daud
Xiaoyun Li
Jedd D. Wolchok
F.S. Hodi
Anthony M. Joshua
S. Ebbinghaus
W. Hwu
C. Robert
Richard W. Joseph
Jeffrey S. Weber
Hassane M. Zarour
M. Dolled-Filhart
Omid Hamid
Richard F. Kefford
A. Ribas
P. Kang
Kenneth Emancipator
K. Gerigich
Peter Hersey
J. Lunceford
Roxana S. Dronca
Source :: European Journal of Cancer. 50:48-49
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Pathology
business.industry
Melanoma
Pembrolizumab
medicine.disease
Ligand (biochemistry)
Internal medicine
medicine
In patient
Pd l1 expression
business
Programmed death

Full Text Access

Tools